ReviewPharmaceuticals (Basel, Switzerland)2021
An Update on the Anticancer Activity of Xanthone Derivatives: A Review.
Review in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 86 citations in OpenAlex.
- Recent advances in Xanthone-based molecular hybrids: emerging therapeutic strategies for multifactorial diseases.Molecular diversity · 2026Review
- Investigation of Antioxidant, In Silico and In Vivo Antiulcer Activities of New Natural Xanthenone and Antracenone Isolated fromMolecules (Basel, Switzerland) · 2026Article
- In Silico Identification of Hydroxyxanthone Derivatives as CDK2/EGFR Dual Inhibitor for Colorectal Cancer Treatment.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Structure Revision of Pyranoxanthones via DFT-AssistedThe Journal of organic chemistry · 2025Article
- Rational Design of Chlorinated Hydroxyxanthone as Anticancer Agent: Molecular Docking, Molecular Dynamic Simulation, ADMET, One-Pot Synthesis, and In Vitro Evaluation.Cell biochemistry and biophysics · 2025Article
- Review
- Asymmetric Synthesis of Cycloartobiloxanthone.Organic letters · 2025Article
- Sensitisation of HeLa Cell Cultures to Xanthone Treatment by RNAi-Mediated Silencing of NANOG and STAT3.Current issues in molecular biology · 2025Article
- Discovery and Validation of Novel Biomarkers for Colorectal Neoplasia Detection via Plasma Metabolomics.MedComm · 2025Article
- Bioactivity of Synthesized Trifluoromethyl Thioxanthone Analogues.Pharmaceuticals (Basel, Switzerland) · 2025Article
- AMTAC-19, a Spiro-Acridine Compound, Induces In Vitro Antitumor Effect via the ROS-ERK/JNK Signaling Pathway.Molecules (Basel, Switzerland) · 2024Article
- Naturally Occurring Xanthones and Their Biological Implications.Molecules (Basel, Switzerland) · 2024Review
- Antioxidant and Anti-Atherosclerosis Activities of Hydrolyzed Jellyfish Collagen and Its Conjugate with Black Jelly Mushroom Extract.Foods (Basel, Switzerland) · 2024Article
- Biological Evaluation of Xanthene and Thioxanthene Derivatives as Antioxidant, Anticancer, and COX Inhibitors.ACS omega · 2023Article
- Xanthone synthetic derivatives with high anticandidal activity and positive mycostatic selectivity index values.Scientific reports · 2023Article
- Potential Antitumor Effect of α-Mangostin against Rat Mammary Gland Tumors Induced by LA7 Cells.International journal of molecular sciences · 2023Article
- Xanthone-1,2,4-triazine and Acridone-1,2,4-triazine Conjugates: Synthesis and Anticancer Activity.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Xanthones: Biosynthesis and Trafficking in Plants, Fungi and Lichens.Plants (Basel, Switzerland) · 2023Review
- Xanthones fromInternational journal of molecular sciences · 2023Article
- Scope and limitations of the preparation of xanthones using Eaton's reagent.Turkish journal of chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
The annual number of cancer deaths continues increasing every day; thus, it is urgent to search for and find active, selective, and efficient anticancer drugs as soon as possible. Among the available anticancer drugs, almost all of them contain heterocyclic moiety in their chemical structure. Xanthone is a heterocyclic compound with a dibenzo-γ-pyrone framework and well-known to have "privileged structures" for anticancer activities against several cancer cell lines. The wide anticancer activity of xanthones is produced by caspase activation, RNA binding, DNA cross-linking, as well as P-gp, kinase, aromatase, and topoisomerase inhibition. This anticancer activity depends on the type, number, and position of the attached functional groups in the xanthone skeleton. This review discusses the recent advances in the anticancer activity of xanthone derivatives, both from natural products isolation and synthesis methods, as the anticancer agent through in vitro, in vivo, and clinical assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.